Neutralisation of uPA with a monoclonal antibody reduces plasmin formation and delays skin wound healing in tPA-deficient mice

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-6

  Jögi, Annika ^a   Rønø, Birgitte ^a,b   Lund, Ida K ^a   Nielsen, Boye S ^a,c   Ploug, Michael ^a   Høyer Hansen, Gunilla ^a   Rømer, John ^a,d   Lund, Leif R ^a,e  

^a FINSEN LABORATORY   (Denmark)

^b LUND UNIVERSITY   (Sweden)

^c Exiqon AS   (Denmark)

^d NOVO NORDISK A S   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MU1; NEUTRALIZING ANTIBODY; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; ENZYME INHIBITION; EPIDERMIS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KERATINOCYTE; MOUSE; NONHUMAN; SKIN INJURY; WOUND HEALING IMPAIRMENT; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; INJURY; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; SERODIAGNOSIS; SKIN; WOUND HEALING;

MURINAE; MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; FIBRINOLYSIN; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTRALIZATION TESTS; SKIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; WOUND HEALING; WOUNDS AND INJURIES;

EID: 77958563278     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012746     Document Type: Article

References (37)

1. Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103: 481-490.
2. Danø K, Rømer J, Nielsen BS, Bjørn S, Pyke C, et al. (1999) Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS 107: 120-127.
3. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174.
4. Page-McCaw A, Ewald AJ, Werb Z (2007) Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8: 221-233.
5. Schäfer M, Werner S (2008) Cancer as an overhealing wound: an old hypothesis revisited. Nature reviews 9: 628-638.
6. Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, et al. (2005) Plasminogen activation and cancer. Thromb Haemost 93: 676-681.
7. Collen D, Lijnen HR (2005) Thrombolytic agents. Thromb Haemost 93: 627-630.
8. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266.
9. Selvarajan S, Lund LR, Takeuchi T, Craik CS, Werb Z (2001) A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation. Nature cell biology 3: 267-275.
10. Bugge TH, Flick MJ, Daugherty CC, Degen JL (1995) Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 9: 794-807.
11. Drew AF, Kaufman AH, Kombrinck KW, Danton MJ, Daugherty CC, et al. (1998) Ligneous conjunctivitis in plasminogen-deficient mice. Blood 91: 1616-1624.
12. Mingers AM, Heimburger N, Zeitler P, Kreth HW, Schuster W (1997) Homozygous type I plasminogen deficiency. Semin Thromb Hemost 23: 259-269.
13. Bugge TH, Lund LR, Kombrinck KK, Nielsen BS, Holmback K, et al. (1998) Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 16: 3097-3104.
14. Lijnen HR, Van Hoef B, Lupu F, Moons L, Carmeliet P, et al. (1998) Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 18: 1035-1045.
15. Solberg H, Rinkenberger J, Danø K, Werb Z, Lund LR (2003) A functional overlap of plasminogen and MMPs regulates vascularization during placental development. Development 130: 4439-4450.
16. Lund LR, Bjørn SF, Sternlicht MD, Nielsen BS, Solberg H, et al. (2000) Lactational competence and involution of the mouse mammary gland require plasminogen. Development 127: 4481-4492.
17. Rømer J, Bugge TH, Pyke C, Lund LR, Flick MJ, et al. (1996) Impaired wound healing in mice with a disrupted plasminogen gene. Nature medicine 2: 287-292.
18. Bugge TH, Kombrinck KW, Flick MJ, Daugherty CC, Danton MJ, et al. (1996) Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 87: 709-719.
19. Green KA, Almholt K, Ploug M, Rønø B, Castellino FJ, et al. (2008) Profibrinolytic effects of metalloproteinases during skin wound healing in the absence of plasminogen. J Invest Dermatol 128: 2092-2101.
20. Rømer J, Lund LR, Eriksen J, Ralfkiaer E, Zeheb R, et al. (1991) Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J Invest Dermatol 97: 803-811.
21. Rømer J, Lund LR, Eriksen J, Pyke C, Kristensen P, et al. (1994) The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J Invest Dermatol 102: 519-522.
22. Grøndahl-Hansen J, Lund LR, Ralfkiaer E, Ottevanger V, Danø K (1988) Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. J Invest Dermatol 90: 790-795.
23. Madlener M, Parks WC, Werner S (1998) Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair. Exp Cell Res 242: 201-210.
24. Lund LR, Rømer J, Bugge TH, Nielsen BS, Frandsen TL, et al. (1999) Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J 18: 4645-4656.
25. Weinberg RA (2007) The Biology of Cancer. Garland Science.
26. Gurtner GC, Werner S, Barrandon Y, Longaker MT (2008) Wound repair and regeneration. Nature 453: 314-321.
27. Lund IK, Jögi A, Rønø B, Rasch MG, Lund LR, et al. (2008) Antibodymediated targeting of the uPA proteolytic function neutralizes fibrinolysis in vivo. J Biol Chem 283: 32506-32515.
28. Bugge TH, Flick MJ, Danton MJ, Daugherty CC, Rømer J, et al. (1996) Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 93: 5899-5904.
29. Lund LR, Green KA, Stoop AA, Ploug M, Almholt K, et al. (2006) Plasminogen activation independent of uPA and tPA maintains wound healing in genedeficient mice. EMBO J 25: 2686-2697.
30. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, et al. (1994) Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368: 419-424.
31. Shulman M, Wilde CD, Köhler G (1978) A better cell line for making hybridomas secreting specific antibodies. Nature 276: 269-70.
32. Jögi A, Pass J, Høyer-Hansen G, Lund LR, Nielsen BS, et al. (2007) Systemic administration of anti-urokinase plasminogen activator receptor monoclonal antibodies induces hepatic fibrin deposition in tissue-type plasminogen activator deficient mice. J Thromb Haemost 5: 1936-1944.
33. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, et al. (1996) Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15: 1572-82.
34. Scott KA, Moore RJ, Arnott CH, East N, Thompson RG, et al. (2003) An antitumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol Cancer Ther 2: 445-451.
35. Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, et al. (2004) Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 5: 348-52.
36. Nielsen BS, Rank F, Illemann M, Lund LR, Danø K (2007) Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ co-express urokinase and urokinase receptor. Int J Cancer 120: 2086-2095.
37. Illemann M, Bird N, Majeed A, Laerum OD, Lund LR, et al. (2009) Two distinct growth patterns of colorectal cancer liver metastasis show differential expression of urokinase, urokinase receptor and plasminogen activator inhibitor-1. Int J Cancer 124: 1860-1870.